Sickle Cell Disease (SCD)

Pathophysiology, crisis management, disease-modifying therapy, and curative gene therapy for the most common inherited hemoglobin disorder

Key Points

• HbS polymerization under deoxygenation causes rigid, sickle-shaped red cells that obstruct microvasculature — driving both vaso-occlusive pain crises and chronic hemolytic anemia.
• Hydroxyurea (hydroxycarbamide) is first-line disease-modifying therapy: raises HbF ≥15%, reduces VOC hospitalizations ~50%, and prolongs survival. It is underused.
• Acute chest syndrome is the leading cause of death in SCD — any new pulmonary infiltrate plus fever, chest pain, or hypoxia requires immediate simple or exchange transfusion and broad-spectrum antibiotics.
• Casgevy (exagamglogene autotemcel, CRISPR-Cas9 gene editing) and Lyfgenia (lovotibeglogene autotemcel, lentiviral gene addition) received FDA approval in December 2023 — the first curative one-time therapies for SCD not requiring a matched donor.
• Allogeneic HSCT from a matched sibling donor remains the most established curative option and is preferred in eligible pediatric patients; outcomes from matched unrelated donors are improving.
• All SCD patients require penicillin prophylaxis through age 5, pneumococcal vaccination, and hydroxyurea counseling regardless of disease severity phenotype.

Pathophysiology

Sickle cell disease results from a single nucleotide substitution (Glu6Val) in the β-globin gene (HBB), producing hemoglobin S (HbS). Under deoxygenated conditions, HbS polymerizes into rigid fibers that distort red blood cells into the characteristic crescent or "sickle" shape. Sickled erythrocytes are rigid, adhere abnormally to vascular endothelium, and have shortened survival (10–20 days vs. 120 days for normal RBCs). Two interrelated pathophysiologic processes drive end-organ damage: **Vaso-occlusion:** Sickled cells obstruct postcapillary venules, triggering ischemia-reperfusion injury…

Clinical Manifestations

**Vaso-occlusive (pain) crisis (VOC):** The hallmark of SCD. Deep, severe pain typically affecting the limbs, back, chest, or abdomen. Precipitated by cold, dehydration, infection, physical stress, or high altitude. Management: aggressive IV or oral hydration, scheduled multimodal analgesia (NSAIDs + opioids; individualize per patient; avoid meperidine due to neurotoxic metabolite accumulation), incentive spirometry to prevent atelectasis. Average hospitalization 5–7 days. **Acute chest syndrome (ACS):** New pulmonary infiltrate plus at least one symptom — fever, chest pain, tachypnea,…

Hydroxyurea — First-Line Disease Modification

Hydroxyurea (hydroxycarbamide) is the cornerstone of SCD disease modification and the most evidence-based intervention for reducing acute complications. Its primary mechanism is induction of fetal hemoglobin (HbF) synthesis — HbF does not participate in HbS polymerization and disrupts sickling even at HbF levels ≥15–20%. **Evidence:** The landmark MSH trial (1995) demonstrated a 50% reduction in VOC frequency, 50% reduction in ACS episodes, and reduced transfusion requirements in adult HbSS. The BABY HUG trial (2011) proved safety and organ-protective effects in infants as young as 9 months.…

Other FDA-Approved Disease-Modifying Agents

Three additional agents beyond hydroxyurea received FDA approval for SCD between 2017 and 2019, expanding the therapeutic armamentarium for patients with inadequate response or hydroxyurea intolerance: **L-Glutamine (Endari) — FDA-approved July 2017:** Oral L-glutamine reduces oxidative stress in sickle erythrocytes by increasing the NAD redox potential. In the pivotal phase 3 trial (Niihara et al., NEJM 2018), L-glutamine reduced the median number of sickle cell crises by 25% and hospitalizations by 33% vs. placebo in patients ≥5 years. Can be used as add-on to hydroxyurea. Dose: 15 g…

Gene Therapy — Casgevy and Lyfgenia

December 2023 marked a pivotal moment in SCD management: the FDA approved two one-time curative gene therapies — the first approvals not requiring a matched donor. **Casgevy (exagamglogene autotemcel, exa-cel) — approved December 8, 2023:** Casgevy uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin (HbF) production. The mechanism: BCL11A is a transcriptional repressor of the γ-globin gene. The therapy disrupts the erythroid-specific enhancer of BCL11A in the patient's own hematopoietic stem cells (HSCs), de-repressing γ-globin and restoring HbF synthesis in red blood cells. The…

Allogeneic Hematopoietic Stem Cell Transplantation

Allogeneic HSCT from a matched sibling donor (MSD) remains the most established curative approach, with long-term event-free survival rates of 90–95% in children and young adults who undergo transplant with an MSD. The challenge: only ~18% of SCD patients have an HLA-identical sibling. **Indications (when to refer):** Recurrent severe VOC (≥3 acute chest syndrome episodes, ≥2 strokes, or frequent hospitalizations despite optimal medical therapy), symptomatic cerebrovascular disease, red cell alloimmunization limiting transfusion therapy, and severe symptomatic anemia. Transplant in pediatric…

Preventive Care and Monitoring

SCD requires lifelong coordinated care across multiple organ systems: **Infection prevention:** - Penicillin V prophylaxis 125 mg twice daily from age 2 months to 3 years, then 250 mg twice daily through age 5 (functional asplenia → susceptibility to encapsulated organisms, especially S. pneumoniae) - Pneumococcal vaccines: PCV15 or PCV20 (per age-appropriate schedule), plus PPSV23 at age 2 and 5 years - Annual influenza vaccine; COVID-19 vaccine series - Meningococcal vaccines (MenACWY and MenB series) **Neurologic monitoring:** - Annual TCD from age 2 through 16: identifies high-risk…